Montréal, July 27,2026 – In 2026, Cingal® reaches an important milestone, celebrating 10 years on the Canadian market. This achievement reflects its continued evolution and its established role in the management of knee osteoarthritis pain.
Launched in Canada in 2016, the first country in the world to introduce this treatment, Cingal® remains the only combination of a corticosteroid and hyaluronic acid delivered in a single injection of its kind in Canada. This therapeutic approach is designed to provide both rapid and sustained pain relief, while offering an effective and convenient treatment option for both patients and clinicians.
Over the years, Cingal® has progressively become integrated into clinical practice, supported by real-world experience, strong partnerships, and the continued trust of healthcare professionals.
“Ten years ago, we launched Cingal® with a clear ambition: to bring forward an innovation that optimizes clinical practice while simplifying the patient journey.
Today, thanks to the strong support of the sports medicine and orthopedic community across Canada, Cingal® has rigorously established itself as a trusted reference in the management of knee osteoarthritis pain.Thank you to all clinicians for your continued confidence, this success is, above all, yours.”, said Martin Drolet, Head of Orthobiologics, Pendopharm, a division of Pharmascience Canada.
On the occasion of this anniversary, the teams would like to express their sincere appreciation to the physicians and healthcare professionals who have contributed to the adoption of Cingal® in their practice. Their commitment plays a key role in improving the quality of life of patients living with osteoarthritis.
“…..As an orthopaedic surgeon who’s been in practice for almost 40 years I have always been keen about the non-operative treatment of knee osteoarthritis pain with hyaluronic acid injections. Since its introduction in 2016, Cingal has provided an additional treatment option that I may consider for appropriate patients.. For the first time in Canada we have a stable combination of a corticosteroid and hyaluronic acid that appears to last up 6 months with each injection. Cingal has become my go to treatment for osteoarthritis pain of the knee.”, said Dr Robert Timothy Deakon, MD, FRCSC, orthopaedic surgeon in sports medicine with the Toronto Argonauts.*
International Recognition Highlighting Growth
This anniversary coincides with recognition on the international stage. At the Anika Therapeutics Distributor Meeting held in Athens, Pendopharm was awarded the Cingal Sales Growth Award.
This distinction reflects the sustained growth of Cingal® and the dedicated efforts of the teams. It also highlights the strength of the partnership with Anika Therapeutics and a shared commitment to expanding access to innovative therapeutic solutions.
Receiving this award as Cingal® celebrates its 10th anniversary offers an opportunity to reflect on the journey since its launch. This recognition is a testament to the hard work, expertise, and engagement of the teams who have contributed to the product’s growth and success.
Cingal® may not be suitable for everyone. Talk to your doctor if you have questions regarding this product, or for more information on pain associated with OA of the knee.
About Pendopharm, a division of Pharmascience Inc.
Pendopharm, the specialty division of Pharmascience Inc., is a leading Canadian pharmaceutical company. Its areas of expertise include gastroenterology, sports medicine and orthopedics, neurology, and cardiology. Pendopharm has extensive experience and strong capabilities to effectively manage its growing product portfolio.
For more information, please visit www.pendopharm.com.
For media inquiries, please contact MediaInquiries@pharmascience.com.
© 2026 Pendopharm, a division of Pharmascience Inc. All rights reserved. CINGAL® is a registered trademark of Anika Therapeutics, Inc., used under license.
About Pharmascience Inc.
Pharmascience Inc. is one of Canada’s largest pharmaceutical manufacturers, with its headquarters located in Montreal. The company delivers high-quality medicines in more than 50 countries. Its global presence and agile business development model support healthcare communities through reliable treatments, made in Canada and designed to meet the evolving needs of patients.
To learn more, visit: www.pharmascience.com.
*Dr Deakon was one of the principal investigators in the 13-01 study conducted by Anika Pharmaceutics.